Dr. Joseph Sokhn
Claim this profileSaint Luke's Hospital
Studies Lung Cancer
Studies Breast Cancer
28 reported clinical trials
87 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage II
Stage III
2Breast Cancer
HER2 positive
Stage IV
ER positive
Affiliated Hospitals
Clinical Trials Joseph Sokhn is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
More about Joseph Sokhn
Clinical Trial Related8 years of experience running clinical trials · Led 28 trials as a Principal Investigator · 12 Active Clinical TrialsTreatments Joseph Sokhn has experience with
- Nivolumab
- Ipilimumab
- Paclitaxel
- Carboplatin
- Biospecimen Collection
- Pembrolizumab
Breakdown of trials Joseph Sokhn has run
Lung Cancer
Breast Cancer
Breast cancer
Cancer
Non-Small Cell Lung Cancer
- Genetic Testing for Early-Stage Lung Cancer
- Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A
- Immunotherapy + Chemotherapy for Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Joseph Sokhn specialize in?
Joseph Sokhn focuses on Lung Cancer and Breast Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage II.
Is Joseph Sokhn currently recruiting for clinical trials?
Yes, Joseph Sokhn is currently recruiting for 12 clinical trials in Chesterfield Missouri. If you're interested in participating, you should apply.
Are there any treatments that Joseph Sokhn has studied deeply?
Yes, Joseph Sokhn has studied treatments such as Nivolumab, Ipilimumab, Paclitaxel.
What is the best way to schedule an appointment with Joseph Sokhn?
Apply for one of the trials that Joseph Sokhn is conducting.
What is the office address of Joseph Sokhn?
The office of Joseph Sokhn is located at: Saint Luke's Hospital, Chesterfield, Missouri 63017 United States. This is the address for their practice at the Saint Luke's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.